Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Adverum Biotechnologies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

INDIANAPOLIS , DEC. 9, 2025 /PRNEWSWIRE/ -- ELI LILLY AND COMPANY (NYSE: LLY) AND ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ: ADVM) TODAY ANNOUNCED THAT THE TENDER OFFER (THE "OFFER") BY FLYING TIGERS ACQUISITION CORPORATION ("PURCHASER"), A DIRECT WHOLLY-OWNED SUBSIDIARY OF LILLY, TO PURCHASE ALL OF THE ISSUED AND OUTSTANDING SHARES ("SHARES") OF ADVERUM'S COMMON STOCK IN EXCHANGE FOR (I) $3.56 PER SHARE, NET TO THE STOCKHOLDER IN CASH, WITHOUT INTEREST AND LESS ANY APPLICABLE TAX WITHHOLDING, PLUS (II) ONE NON-TRADABLE CONTINGENT VALUE RIGHT ("CVR") PER SHARE, WHICH REPRESENTS THE CONTRACTUAL RIGHT TO RECEIVE UP TO TWO CONTINGENT CASH PAYMENTS OF UP TO AN AGGREGATE OF $8.91 PER CVR, NET TO THE STOCKHOLDER IN CASH, WITHOUT INTEREST AND LESS ANY APPLICABLE TAX WITHHOLDING, UPON THE ACHIEVEMENT OF SPECIFIED MILESTONES, EXPIRED AS SCHEDULED AT ONE MINUTE PAST 11:59 P.M., EASTERN TIME, ON DECEMBER 8, 2025 (SUCH DATE AND TIME, THE "EXPIRATION TIME").

LILLY AND ADVERUM ANNOUNCE EXPIRATION AND COMPLETION OF ADVERUM TENDER OFFER AND ACQUISITION

REDWOOD CITY, CALIF., DEC. 01, 2025 (GLOBE NEWSWIRE) -- ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ: ADVM), A CLINICAL-STAGE COMPANY PIONEERING THE USE OF INTRAVITREAL GENE THERAPY AS A POTENTIAL ONE AND DONETMTREATMENT TO PRESERVE SIGHT FOR LIFE, TODAY ANNOUNCED THAT IT HAS MAILED A LETTER TO ITS STOCKHOLDERS IN CONNECTION WITH ITS PENDING TRANSACTION TO BE ACQUIRED BY ELI LILLY AND COMPANY (LILLY).

ADVERUM REMINDS STOCKHOLDERS TO TENDER THEIR SHARES INTO THE OFFER BY LILLY

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF ADVERUM BIOTECHNOLOGIES, INC. (NASDAQCM: ADVM) TO ELI LILLY AND COMPANY (NYSE: LLY). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF ADVERUM WILL RECEIVE $3.56 PER SHARE IN CASH PLUS ONE NON-TRANSFERABLE CONTINGENT VALUE RIGHT (CVR) ENTITLING THE HOLDER TO RECEIVE UP TO AN ADDITIONAL $8.

ADVERUM BIOTECHNOLOGIES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF ADVERUM BIOTECHNOLOGIES, INC. - ADVM

ADVERUM'S LEAD PROGRAM, IXO-VEC, IS A PHASE 3 GENE THERAPY DESIGNED TO TREAT VISION LOSS ASSOCIATED WITH WET AGE-RELATED MACULAR DEGENERATION WITH A SINGLE INTRAVITREAL DOSE ACQUISITION ALIGNS LILLY'S GENETIC MEDICINE CAPABILITIES WITH OPPORTUNITY TO EXPAND GENE THERAPY'S POTENTIAL TO ALLEVIATE THE BURDEN OF AGE-RELATED DISEASES INDIANAPOLISAND REDWOOD CITY, CALIF. , OCT. 24, 2025 /PRNEWSWIRE/ -- ELI LILLY AND COMPANY (NYSE: LLY) AND ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ: ADVM), A CLINICAL-STAGE COMPANY PIONEERING THE USE OF INTRAVITREAL GENE THERAPY WITH THE AIM OF PRESERVING SIGHT FOR LIFE IN HIGHLY PREVALENT OCULAR DISEASES, TODAY ANNOUNCED A DEFINITIVE AGREEMENT FOR LILLY TO ACQUIRE ADVERUM BIOTECHNOLOGIES, INC. ("ADVERUM"), INCLUDING ITS LEAD PRODUCT CANDIDATE, IXO-VEC.

LILLY TO ACQUIRE ADVERUM BIOTECHNOLOGIES

SCREENING CLOSING AHEAD OF EXPECTATIONS, WITH FULL ENROLLMENT NOW ANTICIPATED IN 4Q 2025 (PREVIOUSLY 1Q 2026) ARTEMIS TOPLINE DATA READOUT ACCELERATED TO 1Q 2027 REDWOOD CITY, CALIF., SEPT. 22, 2025 (GLOBE NEWSWIRE) -- ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ: ADVM), A CLINICAL-STAGE COMPANY PIONEERING THE USE OF INTRAVITREAL GENE THERAPY AS A POTENTIAL ONE AND DONETM TREATMENT TO PRESERVE SIGHT FOR LIFE, TODAY ANNOUNCED IT HAS NOTIFIED SITES THAT IT PLANS TO COMPLETE SCREENING IN ARTEMIS, ITS FIRST PIVOTAL PHASE 3 TRIAL EVALUATING IXO-VEC IN WET AGE-RELATED MACULAR DEGENERATION (WET AMD) BY SEPTEMBER 30, SEVEN MONTHS AFTER INITIATION, BECAUSE THE COMPANY NOW EXPECTS FULL ENROLLMENT OF AT LEAST 284 TREATMENT-NAVE AND TREATMENT EXPERIENCED PATIENTS IN 4Q 2025 AND DATA READOUT IN 1Q 2027.

ADVERUM BIOTECHNOLOGIES ANNOUNCES COMPLETION OF SCREENING FOR PIVOTAL PHASE 3 ARTEMIS TRIAL OF IXO-VEC FOR WET AGE-RELATED MACULAR DEGENERATION

REDWOOD CITY, CALIF., SEPT. 05, 2025 (GLOBE NEWSWIRE) -- ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ: ADVM) TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF ADVERUM'S BOARD OF DIRECTORS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 16,860 SHARES OF COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) FOR 8,430 SHARES OF COMMON STOCK TO TWO NEW EMPLOYEES UNDER ADVERUM'S 2017 INDUCEMENT PLAN. THESE AWARDS WERE APPROVED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH ADVERUM IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ADVERUM BIOTECHNOLOGIES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

-ARTEMIS PHASE 3 TRIAL ENROLLMENT EXCEEDING EXPECTATIONS; DRIVEN BY STRONG RETINA SPECIALIST AND PATIENT ENTHUSIASM FOR A POTENTIAL ONE AND DONE THERAPY FOR WET AMD -ARTEMIS ENROLLMENT COMPLETION EXPECTED IN 1Q 2026, WITH TOPLINE DATA ANTICIPATED 1H 2027 -LUNA 2-YEAR LONG-TERM FOLLOW-UP DATA PLANNED IN 4Q 2025 - ANNOUNCED $10 MILLION PRIVATE PLACEMENT WITH FRAZIER LIFE SCIENCES REDWOOD CITY, CALIF., AUG. 12, 2025 (GLOBE NEWSWIRE) -- ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ: ADVM), A CLINICAL-STAGE COMPANY PIONEERING THE USE OF GENE THERAPY TO PRESERVE SIGHT FOR LIFE IN HIGHLY PREVALENT OCULAR DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025.

ADVERUM BIOTECHNOLOGIES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES PIPELINE HIGHLIGHTS

REDWOOD CITY, CALIF., AUG. 06, 2025 (GLOBE NEWSWIRE) -- ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ: ADVM) TODAY ANNOUNCED THAT LAURENT FISCHER, MD, PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND SZILRD KISS, MD, DISTINGUISHED PROFESSOR OF OPHTHALMOLOGY, PROFESSOR OF GENETIC MEDICINE AND BOARD MEMBER OF ADVERUM, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE H.C. WAINWRIGHT 5TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE ON WEDNESDAY, AUGUST 13, 2025 AT 9:00AM EDT.

ADVERUM BIOTECHNOLOGIES TO PARTICIPATE IN THE H.C. WAINWRIGHT 5TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE

REDWOOD CITY, CALIF., JUNE 05, 2025 (GLOBE NEWSWIRE) -- ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ: ADVM) TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF ADVERUM'S BOARD OF DIRECTORS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 9,740 SHARES OF COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) FOR 4,870 SHARES OF COMMON STOCK TO TWO NEW EMPLOYEES UNDER ADVERUM'S 2017 INDUCEMENT PLAN. THESE AWARDS WERE APPROVED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH ADVERUM IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

- INITIATED ARTEMIS, THE FIRST-EVER REGISTRATIONAL INTRAVITREAL GENE THERAPY TRIAL, IN BOTH TREATMENT-EXPERIENCED AND TREATMENT-NAIVE PATIENTS WITH WET AMD - PRESENTED THE FIRST HUMAN DATA MAPPING CELL-LEVEL TRANSDUCTION AND AFLIBERCEPT MRNA EXPRESSION 3.5 YEARS AFTER IXO-VEC ADMINISTRATION, ESTABLISHING THE POTENTIAL FOR LIFE-LONG VISION PRESERVATION REDWOOD CITY, CALIF., MAY 14, 2025 (GLOBE NEWSWIRE) -- ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ: ADVM), A CLINICAL-STAGE COMPANY PIONEERING THE USE OF GENE THERAPY TO PRESERVE SIGHT FOR LIFE IN HIGHLY PREVALENT OCULAR DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025.

Adverum Biotechnologies, Inc.

ADVM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Adverum Biotechnologies, Inc.

ADVM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ADVM